Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma
Clinical trial NCT04715217 · UNKNOWN
Trial details
- NCT number
- NCT04715217
- Sponsor
- Shanxi Province Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-01-04
- Primary completion
- 2024-10-31
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.